KLOW Blend (GHK-Cu · KPV · BPC-157 · TB-500)

KLOW Blend is a research-chemical mixture of four peptides — GHK-Cu, KPV, BPC-157, and TB-500 — combined and marketed for skin, inflammation, and tissue-repair research. It is not an FDA-approved product, and the blend has not been studied as a single combination in humans. This page is for education only and is not medical advice; any decision about these compounds should be made with a licensed clinician.

What is KLOW Blend?#

KLOW Blend is an unofficial, informally named combination product rather than a single defined drug. The name is an acronym drawn from its four components, which have each been studied separately:

• GHK-Cu — a naturally occurring copper-binding tripeptide (glycine-histidine-lysine) best known as a cosmetic skincare ingredient and studied for skin remodeling and wound healing.
• KPV — a tripeptide (lysine-proline-valine) corresponding to the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), studied in cell and animal models for anti-inflammatory activity.
• BPC-157 — a synthetic peptide derived from a sequence found in human gastric juice ("body protection compound"), studied mostly in animals for gut and connective-tissue healing.
• TB-500 — a synthetic peptide fragment related to thymosin beta-4, studied in animal and cell models for cell migration, blood-vessel formation, and wound repair.

The blend is typically sold as a lyophilized (freeze-dried) powder labeled "for research use only." There is no standardized formula, ratio, or manufacturer specification, so the exact contents and proportions can vary between sources.

How does KLOW Blend work?#

There is no established mechanism for the blend as a whole, because it has not been studied as a combination. What is known comes from research on the individual components, mostly in cells and animals:

• GHK-Cu appears to influence the extracellular matrix, supporting collagen and elastin synthesis and modulating remodeling enzymes; it also shows antioxidant and angiogenic activity in laboratory and animal studies.
• KPV has been described as suppressing pro-inflammatory signaling — notably the NF-κB pathway and cytokines such as TNF-α — while retaining the anti-inflammatory properties of its parent hormone α-MSH without the pigment-signaling effects.
• BPC-157 has been described in animal studies as interacting with growth-factor and nitric-oxide signaling pathways, with reported cytoprotective effects on gut, tendon, and other tissues.
• TB-500 corresponds to an actin-binding region of thymosin beta-4 and is studied for promoting cell migration and tissue repair.

The idea behind combining them is that complementary repair and anti-inflammatory pathways might reinforce one another. This rationale is theoretical — no human study has confirmed that the combination works, is safe, or offers any advantage over the individual peptides.

What is KLOW Blend studied for?#

The blend itself has not been the subject of published clinical research. The table below summarizes the research themes for the individual components and the level of human evidence behind each.

The clearest takeaway is that human evidence is thin even for the single peptides, and effectively absent for the combination.

Is KLOW Blend legal and FDA-approved?#

KLOW Blend is not FDA-approved, and the FDA has never evaluated the combination. Looking at each component:

• GHK-Cu is used as a cosmetic ingredient, which in the U.S. does not require pre-market drug approval; it is not an approved drug, and injectable research-chemical forms are not approved for human use.
• KPV is an unapproved research chemical with no therapeutic approval in any country.
• BPC-157 is an unapproved drug. In 2023 the FDA placed it in Category 2 of its interim list of bulk drug substances for compounding, citing concerns about immune reactions, impurities, and a lack of human safety data. (It was later removed from Category 2 on procedural grounds in 2026, but that is not approval — it remains unapproved and investigational.)
• TB-500 is an unapproved research chemical with no therapeutic approval in any country.

For athletes, BPC-157 and TB-500 are on the World Anti-Doping Agency (WADA) Prohibited List (BPC-157 under category S0, unapproved substances), so use can lead to sanctions. These peptides are commonly sold "for research use only," which is not a clearance for human use. Legal status varies by jurisdiction, so check local law and consult a licensed clinician.

How is KLOW Blend dosed in research?#

There is no validated human dose for KLOW Blend or any of its components. Because the blend is unapproved and unstudied in humans, no established, evidence-based dosing exists, and the safe-versus-harmful boundary is unknown. WikiPeps does not publish dosing protocols, amounts, schedules, or "cycles" for unapproved compounds. Any dosing question should be directed to a licensed clinician who can weigh an individual's circumstances; nothing on this page should be read as a dose or a recommendation to use.

How is KLOW Blend reconstituted?#

If a research product arrives as a lyophilized powder, the general reconstitution principles are the same as for other peptides: bring everything to room temperature, disinfect the stoppers, add bacteriostatic water slowly down the vial wall, and swirl gently rather than shake. Because this blend contains GHK-Cu, the solution may take on a faint blue tint from the copper ion, which is expected. For the full process, see our reconstitution guide. This is provided for education only and is not an instruction to prepare or self-administer any substance.

What are the safety considerations?#

The safety of KLOW Blend in humans is largely uncharacterized, and combining four active peptides adds uncertainty rather than removing it. Key considerations include:

• No human safety data for the blend, and limited data for the individual injectable peptides.
• Possible immune reactions — a concern the FDA specifically raised for BPC-157.
• Product quality risks — research chemicals are not held to pharmaceutical manufacturing standards, so impurities, mislabeling, or inaccurate contents and ratios are real possibilities.
• Injection and sterility risks — any injectable carries infection, irritation, and contamination risks.
• Unknown interactions — among the four peptides themselves, with medications, and with underlying health conditions.
• Anti-doping exposure — BPC-157 and TB-500 are WADA-prohibited.

Anyone with a medical condition, who is pregnant or breastfeeding, or who takes other medications should be especially cautious. A licensed clinician should be consulted before considering any use.

The bottom line#

KLOW Blend is an unofficial research-chemical mixture of GHK-Cu, KPV, BPC-157, and TB-500, grouped because each has been studied separately for repair or inflammation. It is not FDA-approved, has no published human studies as a combination, and its components include unapproved research chemicals that are also WADA-prohibited. Human evidence is thin for the single peptides and absent for the blend, and its safety is largely unknown. Use this page for education only, do not treat it as a dose or a recommendation, and consult a licensed clinician before making any health decision.